Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v8-EN Version v2-FR
Language English French
Date Updated 2025-07-05 2025-06-16
Drug Identification Number 02251930 02251930
Brand name LANTUS LANTUS
Common or Proper name INSULIN GLARGINE INSULIN GLARGINE
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients INSULIN GLARGINE INSULIN GLARGINE
Strength(s) 100UNIT 100UNIT
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS
Packaging size 3 mL 3 mL
ATC code A10AE A10AE
ATC description INSULINS AND ANALOGUES INSULINS AND ANALOGUES
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2025-06-16 2025-06-16
Actual start date 2025-06-16 2025-06-16
Estimated end date Unknown Unknown
Actual end date 2025-07-04
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments Supply delay. The shortage is only applicable to the cartridge product at this time. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. Supply delay. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy.
Health Canada comments